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Abstract
Background: Chromium (Cr) is an essential trace element that has garnered interest for use as a weight loss aid,
but its molecular mechanism in obesity is not clear. In this study, an attempt has been made to investigate the
effects of chromium histidinate (CrHis) on glucose transporter-2 (GLUT-2), nuclear factor erythroid 2-related
factor 2 (Nrf2), heme oxygenase-1 (HO-1), nuclear factor-kappa B (NF-B p65) and the oxidative stress marker
4-hydroxynonenal adducts (HNE) expressions in liver of rats fed high fat diet (HFD).
Methods: Male Wistar rats (n = 40, 8 wk-old) were divided into four groups. Group I was fed a standard diet
(12% of calories as fat); Group II was fed a standard diet and supplemented with 110 μg CrHis/kg BW/d; Group III
was fed a HFD (40% of calories as fat); Group IV was fed HFD and supplemented with 110 μg CrHis/kg BW/d.
Results: Rats fed HFD possessed greater serum insulin (40 vs.33 pmol/L) and glucose (158 vs. 143 mg/dL)
concentration and less liver Cr (44 vs.82 μg/g) concentration than rats fed the control diet. However, rats
supplemented with CrHis had greater liver Cr and serum insulin and lower glucose concentration in rats fed HFD
(P < 0.05). The hepatic nuclear factor-kappa B (NF-B p65) and HNE were increased in high fat group compared to
control group, but reduced by the CrHis administration (P < 0.05). The levels of hepatic Nrf2 and HO-1 were
increased by supplementation of CrHis (P < 0.05).
Conclusion: These findings demonstrate that supplementation of CrHis is protective against obesity, at least in
part, through Nrf2-mediated induction of HO-1 in rats fed high fat diet.
Background
T h eg l o b a lp r e v a l e n c eo fo v e r w e i g h ta n do b e s i t yi s
increasing rapidly worldwide among adults as well as
among children and adolescents in places where high
dietary fat intake and this is leading to dramatic
increases in complications such as hyperlipidemia [1],
fatty liver [2], type II diabetes mellitus [3] and cardiovas-
cular diseases [4]. High-fat diet (HFD) is associated with
alterations in liver chemistry and structure, increased
risk of liver damage ranging from steatosis to steatohe-
patitis, cirrhosis, and even hepatocellular degeneration.
High dietary fat intake is considered to be an important
factor in the development of insulin resistance [5-7],
oxidative stress [8], inflammation, abnormal mitochon-
dria, and increased collagen content [9,10]. Elevated
levels of oxidative stress can potentially impair cellular
glucose metabolism via a variety of mechanisms, includ-
ing redox imbalance and insulin resistance.
Several pharmacological agents such as insulin-sensi-
tizing agents may be used to reduce or control the body
weight and obesity. One of such agents, chromium (Cr)
h a sb e e ne x a m i n e di ns o m ea n i mal studies and clinical
studies for its anti-obesity effects [11]. Cr is essential for
the maintenance of normal metabolism of carbohydrate
and lipids [12]. Inadequate amounts of Cr may result in
improper functioning of the metabolic process and lead
to a number of physiological disorders that increase risk
for diabetes and cardiovascular diseases including ele-
vated circulating insulin, glucose, triglycerides, total cho-
lesterol, reduced HDL-cholesterol and impaired immune
function [12,13]. Laboratory and clinical evidence indi-
cate that chromium supplementation may improve insu-
lin sensitivity by enhancing intracellular signaling
[14,15]. Cr complexes have also been shown to reduce
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any medium, provided the original work is properly cited.oxidative stress in diabetic rats [16,17]. Chromium histi-
dinate (CrHis) is a stable compound with a better
absorption than other forms of chromium compounds
tested in human subjects [18]. Anderson et al. [18]
o b s e r v e dt h a tm e na n dw o m e na b s o r b e da na v e r a g e
3.1 mcg of Cr from the CrHis complex, compared to
1.8 mcg from chromium picolinate (CrPic), 0.4 mcg
from chromium chloride and 0.2 mcg from chromium
polynicotinate. Cr may attenuate some effects of a HFD,
mainly body fat accretion [19].
Nuclear factor-kappa B (NF-B p65) and nuclear fac-
tor-E2-related factor 2 (Nrf2) have been drawn an
increasing attention for their role in protecting tissue
injury such as liver disorders [20]. Nuclear factor-kappa
B, crucial for the priming phase of liver regeneration,
has been shown to be involved in promoting hepatocyte
proliferation and inhibiting apoptosis of liver cells
[20,21]. Nuclear factor-E2-related factor 2 is a transcrip-
tion factor that is activated by oxidative stress and elec-
trophiles that regulates the expression of numerous
detoxifying and antioxidant genes. Studies have shown
that Nrf2 protects the liver from xenobiotic toxicity
[22,23], and it was reported that HFD reduced the
mRNA expression of Nrf2 and its target genes in mice
[23]. The synthetic oleanolic triterpenoid 1-[2-cyano-
3,12-dioxooleana-1,9 (11)-dien-28-oyl]imidazole (an
extremely potent activator of Nrf2 signaling) effectively
prevents increase in the body weight following a high-
fat diet, showing that Nrf2 can be an attractive target
for management of obesogenesis [22]. However, the
effects of Cr supplementation on liver NF-B, Nrf2 and
HO-1 activation in rats fed a HFD are not known. In
this study, it has been investigated the effects of a HFD
on glucose metabolism, liver damage and oxidative
stress, and to further examine whether this damage
could be repaired by CrHis. Accordingly, the effects of
CrHis on liver tissue were determined in the context of
indices of oxidative stress (HNE) and inflammation (e.g.,
hepatic expression of NF-B).
Methods
Animals and diets
Male Wistar rats (n = 40, 8 weeks old) weighing 200-215 g
were purchased from Firat University Laboratory Animal
Research Center (Elazig, Turkey). The animals were
housed at the temperature of 22 ± 2°C, humidity of 55 ±
5%, and with a 12/12 h light/dark cycle throughout the
experiment. The experiment was conducted under the
protocol approved by the Firat University. All procedures
involving rats were conducted in strict compliance with
relevant laws, the Animal Welfare Act, Public Health Ser-
vices Policy, and guidelines established by the Institutional
Animal Care and Use Committee of the university. Rats
were fed standard diet (12% of calories as fat) or high fat
diet (HFD, 40% of calories as fat). During the animal
experimentation, rats in the treatment groups were
supplemented with CrHis (Nutrition 21, NY, USA) via
drinking water. Ingredients and chemical composition of
the basal (control) diet are shown in Table 1. The diets
were stored at 4°C cold chamber.
Experimental Design
After 1 week of adaptation period, the rats were ran-
domly divided into four groups as (i) control group: rats
were fed a standard diet (12% of calories as fat);
(ii) CrHis group: rats weref e dt h es t a n d a r dd i e ta n d
received CrHis; (iii) HFD group: rats were fed a high-fat
diet (40% of calories as fat); (iv) HFD+CrHis group: rats
were fed a high-fat diet (40% of calories as fat) and
received CrHis. CrHis (Nutrition 21, Inc., Purchase, NY,
USA) was dissolved in water and administered at a
concentration of 110 μg/kg.d in the drinking water con-
taining 5.53 μgC r / Lf o r1 2w e e k st og e t8μgC r / d a y
which is an equivalent dose of 560 μgC rf o ra7 0k g
adult human [17].
Laboratory Analyses
For the measurement of biochemical markers, blood
samples were collected from the tail vein of each rat
prior to scarification by cervical dislocation. Blood sam-
ples were centrifuged at 3000 g for 10 min and sera
were separated. Fasting glucose concentrations were
determined at euthanasia, using the glucose-oxidase
method and reading in a glucometer (Accu-chek, Roche
Diagnostic, Germany). Serum insulin (Linco Research
Inc, St. Charles, MO, USA) concentration was measured
by ELISA (ELx-800, Bio-Tek Instruments Inc, City, VT,
USA).
Table 1 Ingredient and nutrient composition of the diets
Ingredients (g/kg) Normal Diet High-Fat Diet (HFD)
Casein 200.0 200.0
Starch 615.0 145.0
Sucrose - 150.0
Corn oil 80.0 -
Beef tallow - 400.0
Cellulose 50.0 50.0
Vitamin-Mineral Premix
1 50.0 50.0
DL-Methionine 3.0 3.0
Choline chloride 2.0 2.0
Chromium, mg/kg 0.066 0.097
1The vitamin-mineral premix provides the following (per kg): all-trans-retinyl
acetate, 1.8 mg; cholecalciferol, 0.025 mg; all-rac-a-tocopherol acetate,
12,5 mg; menadione (menadione sodium bisulfate), 1.1 mg; riboflavin, 4.4 mg;
thiamine (thiamine mononitrate), 1.1 mg; vitamin B-6, 2.2 mg; niacin, 35 mg;
Ca-pantothenate, 10 mg; vitamin B-12, 0.02 mg; folic acid, 0.55 mg; d-biotin,
0.1 mg. manganese (from manganese oxide), 40 mg; iron (from iron sulfate),
12.5 mg; zinc (from zinc oxide), 25 mg; copper (from copper sulfate), 3.5 mg;
iodine (from potassium iodide), 0.3 mg; selenium (from sodium selenite),
0.15 mg; choline chloride, 175 mg.
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(65% Merck, Darmstadt, Germany) and H2O2 (30%
Merck) in a Microwave Digestion System (Berghoff,
Eningen, Germany), liver samples and blood sera were
analyzed for Cr content using graphite furnace atomic
absorption spectrophotometer (AAnalyst 800, Perkin-
Elmer Corp., Norwalk, CT, USA) as described by
Dogukan et al. [24].
Western blot analyses
Liver samples were also analyzed for the expression of
GLUT-2, NF-B, Nrf2, HO-1 and HNE using the wes-
tern blot technique. In all groups, the liver was removed
from sacrificed rats. Small pieces of the liver samples in
each group of animals were pooled together for Western
blot analysis. Protein extraction was performed as fol-
lows: The sample was homogenized in 1 ml ice-cold of
hypotonic buffer A [10 mM HEPES (pH 7.8), 10 mM
KCl, 2 mM MgCl2, 1 mM DTT, 0.1 mM EDTA,
0.1 mM phenylmethylsulfonyl-fluoride (PMSF)]. 80 μlo f
10% Nonidet P-40 (NP-40) solution was added to the
homogenates, and the mixture was then centrifuged for
2 min at 14,000 g. The supernatant was collected as a
cytosolic fraction for the analysis of GLUT-2, HO-1 and
HNE. The precipitated nuclei were washed once with
500 μl of buffer A plus 40 μl of 10% NP-40, centrifuged,
resuspended in 200 μl of buffer C [50 mM HEPES (pH
7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM
DTT, 0.1 mM PMSF, 20% glycerol] and centrifuged for
5 min at 14,800 g. The supernatant containing nuclear
proteins was collected for the analysis of Nrf2 and NFkB
p65 [25]. Concentration of the protein was determined
according to the procedure described by Lowry et al.
[26] using a protein assay kit supplied by Sigma,
St. Louis, MO, USA. Sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis sample buffer containing 2%
b-mercaptoethanol was added to the supernatant. Equal
amounts of protein (50 μg) were electrophoresed and
subsequently transferred to nitrocellulose membranes
(Schleicher and Schuell Inc., Keene, NH, USA). Nitro-
cellulose blots were washed twice for 5 min each in PBS
and blocked with 1% bovine serum albumin in PBS for
1 h prior to application of the primary antibody. The
antibody against Nrf2 and HNE was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Antibody against GLUT-2, NF-Ba n dH O - 1w a sp u r -
chased from Abcam (Cambridge, UK). Primary antibody
was diluted (1:1000) in the same buffer containing
0.05% Tween-20. The nitrocellulose membrane was
incubated overnight at 4°C with protein antibody. The
blots were washed and incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG (Abcam,
Cambridge, UK). Specific binding was detected using
diaminobenzidine and H2O2 as substrates. Protein
loading was controlled using a monoclonal mouse anti-
body against b-actin antibody (A5316; Sigma). Blots
were performed at least three times to confirm the
reproducibility of the results. Bands were analyzed den-
sitometrically using an image analysis system (Image J;
National Institute of Health, Bethesda, USA).
Statistical analysis
The data were analyzed using the General Linear Model
(GLM) procedure of SAS software [27]. Significant dif-
ferences at 5% among treatment means were determined
using Fisher’s post hoc test for all groups.
Results
Glucose, Insulin and Cr Levels
As shown in Table 2 the measurement of the total body
weight revealed that rats fed HFD were heavier than the
control rats (317 vs. 262 g). In addition, rats fed HFD
had higher serum insulin (40 vs. 33 pmol/L) and glucose
concentration (158 vs. 143 mg/dL), and less liver Cr
concentration (44 vs.8 2μg/g) than rats fed a control
diet (Table 2) (P < 0.05). CrHis administration in the
control group did not affect body weight, insulin and
glucose levels in the serum but did increase Cr concen-
tration in the liver. CrHis administration significantly
reduced the total body weight and glucose level in rats
fed HFD (Table 2). However, HFD rats supplemented
with CrHis had higher liverC ra n ds e r u mi n s u l i nt h a n
rats fed HFD (P < 0.05) (Table 2).
Western Blots Analyses of GLUT-2, Nrf2, HO-1, NF-B p65
and HNE
Figure 1 shows the effects of CrHis on GLUT-2, Nrf2,
HO-1 and NF-B expression in the liver of rats by wes-
tern blot. Based on band densities, liver GLUT-2 expres-
sion was significantly decreased in rats fed HFD diets
compared to the control rats (Figure 1A). However, pro-
tein expression of GLUT-2 in the liver was increased to
the normal level in the rats fed HFD by CrHis supple-
mention (Figure 1A). The expression of NF-Bi nl i v e r
Table 2 The effect of CrHis supplementation on levels of
glucose, insulin and liver Cr in rats fed the high-fat diet
(n = 10)
Items Groups
Control CrHis HFD HFD+ CrHis
Body mass, g 265 ± 6.5
c 262 ± 5.8
c 317 ± 5.3
a 293 ± 4.2
b
Insulin, pmol/L 33.5 ± 0.3
c 33.9 ± 0.1
c 39.3 ± 0.2
a 40.6 ± 0.2
b
Glucose, mg/dl 125 ± 5.1
c 122 ± 6.9
c 158 ± 4.6
a 143 ± 5.2
b
Liver Cr, μg/g 55.4 ± 3.8
c 82.3 ± 2.2
a 44.6 ± 4.6
d 61.3 ± 3.1
b
a-c: Means in the same line without a common superscript differ significantly
(P < 0.05).
HFD: High fat diet.
CrHis: Chromium histidinate.
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Figure 1 Effect of HFD and CrHis on liver GLUT-2 (A), NFB (B), Nrf2 (C), HO-1 (D) and HNE (E) expressions in rats fed high fat diet.
The intensity of the bands was quantified by densitometric analysis and normalized with corresponding b-actin. Values are means ± standard
error of the mean. Western blot analysis was repeated at least 3 times (n = 3) and a representative blot is shown. Data points with different
superscripts are significantly different at the level of p < 0.05 by Fisher’s multiple comparison test.
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sion of NF-B compared to the control (P < 0.05). How-
ever, the increased NF-B expression in liver after HFD
treatment was decreased by CrHis treatment (P < 0.05)
(Figure 1B). The accumulation of Nrf2 in the nuclear
fraction and HO-1 was significantly lower in liver of
HFD-treated rats than that of the control rats (P < 0.05)
(Figure 1C and 1D). In the group of rats fed HFD
+CrHis, however, Nrf2 accumulation in the nuclear frac-
tion of liver was significantly increased as compared to
HFD treatment alone (P < 0.05), but it was lower than
that of seen in the control group (Figure 1C). HO-1
expression of the HFD-induced liver injury group was
statistically lower than control (P < 0.05), whereas there
was a significant increase in the level of HO-1 expres-
sion between the HFD-induced liver injury group and
the HFD+CrHis-treated group (P < 0.05) (Figure 1D).
The analysis of expression of HNE by western blot in
liver showed that high dietary fat intake increased the
protein expression of HNE compared to the levels seen
in the control (P < 0.05) (Figure 1E). However, the
increased HNE expression in liver after HFD treatment
was decreased by CrHis treatment (P <0 . 0 5 )( F i g u r e
1E).
Discussion
Insulin resistance has been shown to be the major con-
tributing factor to the metabolic syndrome, which com-
prises a cluster of risk factors for conditions such as
obesity, dyslipidemia, hypertension, and hyperglycemia
[10,28]. Previous studies showed that a high fat diet can
lead to visceral obesity in rodent animal models [29-31].
Dietary trivalent Cr has been shown to play an impor-
tant role in metabolic disorders associated with insulin
resistance and hyperglycemia by providing significant
beneficial effects in the insulin system [32]. Cr acts by
interfering with the number of receptors accessible to
insulin, modulation of their affinity to the hormone, and
the disruption of intracellular signal transduction
[15,33,34]. Cr supplementation has been also shown to
inhibit increase in inflammatory markers and oxidative
stress levels in cultured monocytes exposed to high glu-
cose levels [17,35,36]. The purpose of the current study
w a st oe x a m i n ew h e t h e rC r H i sc o u l dp l a yar o l ei nt h e
prevention of liver damage of rats fed a HFD.
It has been shown that a HFD results in significant
increase in body weight, blood glucose and insulin levels
[37,38]. In the present study, it has been observed that
CrHis supplementation reduced serum levels of glucose
and increased serum insulin and liver Cr levels in rats
fed HFD (Table 2). The mechanisms of Cr action on
insulin signaling pathways have been extensively studied
over recent years. These effects appear to be related to
an increase in insulin sensitivity, with the mechanisms
explained recently in great detail by Vincent and Ben-
nett [39]. Chromium is thought to increase both the
binding of insulin to its cell surface receptors, and the
number of insulin receptors [14]. Similar results demon-
strating the ability of chromium to improve glucose and
insulin tolerance and to reduce blood glucose and lipids
have been previously reported [17,40-42]. Daily supple-
mentation of trivalent Cr-containing milk powder
reduced serum levels of glucose, insulin and triglycer-
ides, and improved glucose and insulin tolerance [43].
The present study has shown that CrHis supplementa-
tion induced GLUT-2 activity, increased Nrf2 and HO-1
expression and downregulated NF-B and HNE activity
in liver of rats fed by HFD (Figure 1). Glucose transpor-
ter-2 is the major glucose transporter protein involved
in transport of glucose across hepatocyte, either from
inside or outside depending upon the insulin stimuli.
There was no previous study investigating the effects of
Cr supplementation on the GLUT-2 in liver with which
to compare this study. However, CrPic was reported to
enhance skeletal muscle glucose transporter-4 (GLUT-4)
translocation and insulin sensitivity in a rat model of
obesity and insulin resistance [44] and also recruits
intracellular localization ofG L U T - 4t ot h ec y t o p l a s m i c
side of the plasma membrane of murine adipocytes [45].
In a similar experiment, improvement in glucose toler-
ance was attributed to enhanced membrane-associated
GLUT-4 in obese rats after insulin stimulation [44]. Cr
supplementation activated postreceptor insulin signaling
such as increasing insulin resistance-associated (IRS1)
and GLUT-4 expression, stimulating phosphoinositide
3-kinases (PI3-K) and Akt activity, downregulating c-Jun
N-terminal kinases (JNK) activity and decreasing IRS1
phosphorylation in skeletal muscles [43].
It has been reported that high dietary fat intake pro-
moted inflammation and NF-B activation [46]. Nuclear
factor-kappa B in most cells is bound with an inhibitory
protein of nuclear factor-B( I B) to form a latent, inac-
tive transcription factor in the cytoplasm. In the case of
oxidative stress and various cytokines, NF-B is released
rapidly from IB to activate the gene expression of sev-
eral cytokines, chemotactic and matrix proteins involved
in inflammation, immunological responses and/or prolif-
eration [8,34]. The results have shown that consumption
of a HFD enhanced NF-B p65 subunit activation in rat
liver, which supports our observation of high fat diet-
induced oxidative stress. Fan et al. [47] reported that
NF-B binding activity was higher in the rats fed HFD
diet than that in the controls. However, the effect of
CrHis on the NF-B pathway is still unclear. Similarly,
Cr dinicocysteinate -treated rats showed decreased levels
of activated NF-B when compared to diabetic rats [34].
Recent research has identified Nrf2 as a key transcrip-
tion factor for combating hepatic oxidative stress [48].
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antioxidant response element (ARE)-dependent gene
regulation in response to oxidative stress. Nrf2 seques-
tered in the cytoplasm by the cytosolic repressor Kelch-
like ECH-associated protein 1 (Keap 1) plays an impor-
tant role in the maintenance of the cellular redox bal-
ance. Keap1 links Nrf2 to the cytoskeleton to retain
Nrf2 in the cytoplasm, thereby promoting its degrada-
tion. Oxidative stress facilitates Nrf2 to escape Keap1-
mediated proteasomal degradation, leading to Nrf2 sta-
bilization, subsequent nuclear translocation, and binding
to ARE [49]. Nrf2 induces expression of antioxidant
enzymes and phase II detoxifying proteins, such as
heme oxygenase-1 by binding to antioxidant responsive
elements in the promoters of these genes [48]. However,
it is not known whether CrHis plays a role in the Nrf2/
HO-1 pathway in liver. The present study demonstrates
for the first time that supplementing CrHis increases
expression of Nrf2 and HO-1 in liver of rats fed HFD
(Figure 1). This finding suggests that Cr may be
involved in stabilization and activation of Nrf2. How-
ever, Nrf2 plays a protective role against liver injury by
regulating expression of antioxidant genes and phase II
drug-metabolizing enzymes in liver [50]. On the other
hand, Nrf2 inhibits lipid accumulation and oxidative
stress in mouse liver after feeding a HFD, probably by
interfering with lipogenic and cholesterologenic path-
ways [23].
Several studies have shown elevated oxidative stress
markers in obesity [51-53]. High intake of dietary fat
enhances ROS overproduction which increases lipid per-
oxidation [46]. Increased body fat stimulates excessive
reactive oxygen species production by NADPH oxidase
activation [54]. The reaction of free radicals with mem-
brane lipids causes the formation of lipid peroxidation
products including several aldehydic compounds, one of
which is highly toxic and called 4-hydroxynonenal
(HNE). 4-hydroxynonenal is frequently measured as
indicators of lipid peroxidation and oxidative stress
in vivo and is considered as an index of oxidative stress.
In the present study, expression of HNE in liver of rats
fed HFD decreased when dietary CrHis was supple-
mented. CrHis supplementation did not alter these
parameters in control rats. Significantly lower expres-
sion of HNE was observed in animals receiving CrHis
supplementation. These findings indicate significant
positive associations between CrHis intake and HNE
expression for rats fed high fat diets. Cr, an insulin
cofactor, is postulated to function to augment antioxi-
dant defense system [17,36]. Similar results have been
reported by Preuss et al. [16] who have explained a
decrease in hepatic TBARS formation by supplementa-
tion of CrPic and chromium nicotinate in rats. Simi-
larly, Cr dinicocysteinate significantly reduced lipid
peroxidation and increased blood vitamin C and adipo-
nectin levels in ZDF rats [34].
Conclusion
The present investigation has shown that high dietary
fat intake can induce changes in metabolic profile such
as increased body weight, serum insulin and glucose
concentrations, and decreased liver chromium concen-
trations and glucose transporter-2, Nrf2, HO-1 expres-
sions and increased NF-B and HNE expressions. These
adverse alterations could be partially reversed by the
supplemental CrHis. These results suggest that supple-
mentation of CrHis would be effective on protection of
obesity through Nrf2-mediated induction of heme oxy-
genase-1 in subjects when fed with HFD.
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